Helmholtz Diabetes Center
Helmholtz Institute for Metabolic, Obesity, and Vascular Research
The Helmholtz Institute for Metabolic, Obesity, and Vascular Research (Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung, HI-MAG) in Leipzig investigates molecular mechanisms linking adipose tissue dysfunction to metabolic and vascular diseases.
The Helmholtz Institute for Metabolic, Obesity, and Vascular Research (Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung, HI-MAG) in Leipzig investigates molecular mechanisms linking adipose tissue dysfunction to metabolic and vascular diseases.
Take a look at our Metabolic Chambers:
Bioinformatics Core Unit
Our institute is supported by an expert group of bioinformaticians. Learn more about the people and their projects here.
Clinical Trial Unit
Our clinical studies are part of our Clinicial Trial Unit and carried out in cooperation with the Leipzig Medical Center. For further information, please click here.
Director of the Helmholtz Institute for Metabolic, Obesity and Vascular Research and Head of Research Group Clinical Obesity Research, HI-MAG
View profile
HI-MAG Institute's Manager
Group Leader of Adipose Tissue Microarchitecture and Metabolism, HI-MAG
View profilePublications of HI-MAG
Luther, M. ; Wittig, T. ; Winther, B. ; Fischer, A. ; Düsing, S. ; Branzan, D. ; Doß, M. ; Schmidt, A. ; Scheinert, D. ; Steiner, S.
Five-year outcomes of endovascular aortoiliac reconstruction in complex lesions: A retrospective single-center study.Mora, P. ; Aroda, V.R. ; Asong, M. ; Blüher, M. ; Carlander, A.L.F. ; Kaltoft, M. ; Vilsen, L.N. ; Rosenstock, J.
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: A multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Mora, P. ; Aroda, V.R. ; Asong, M. ; Blüher, M. ; Heftdal, L.D. ; Carlander, A.L.F. ; Vilsen, L.N. ; Rosenstock, J.
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: A multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Kleißen, J. ; Goerdeler, C. ; Aldehoff, A.S. ; Karkossa, I. ; Didio, A. ; Schmidt, J. ; Kalkhof, S. ; Lehmann, J. ; Rolle-Kampczyk, U. ; Grimaldi, M. ; Balaguer, P. ; Faissner, M. ; Flamm, C. ; Wabitsch, M. ; Heiker, J.T. ; Schubert, K. ; von Bergen, M.
Halogenated bisphenol A alternatives inhibit aldo-keto reductase 1C1 and induce metabolic alterations in human adipocytes.Schurfeld, R. ; Baalmann, F. ; Baratashvili, E. ; Sandner, B. ; Bachmann, A. ; Weiner, J. ; Wurfel, M. ; Wendt, R. ; Haussmann, M. ; Bast, I. ; Beige, J. ; Kosacka, J. ; Klöting-Blüher, N. ; Krohn, K. ; Kirsten, T. ; Zhang, M. ; Harris, R.C. ; Isermann, B. ; Kovacs, P. ; Blüher, M. ; Stumvoll, M. ; Tonjes, A. ; Heiker, J.T. ; Ebert, T.
Inverse association of circulating kallikrein-related peptidase 7 with renal function and mortality risk in patients with chronic kidney disease.Goergen, A. ; Challa, T.D. ; Villaroel‐Vicente, C. ; Borsigova, M. ; Krieken, P.P.v. ; Wolfrum, C. ; Blüher, M. ; Wueest, S. ; Konrad, D.
ASK1 ‐induced FGF21 synthesis in the liver Ppevents obesity in mice.Galia, S. ; Crescenzi, R. ; Kruppa, P. ; Kartt, J. ; Cochrane, J.C. ; Mascio, C. ; Harmacek, L. ; Heil, S. ; Samouhos, E. ; Peterson, S. ; Dean, S.M. ; Wright, T.F. ; Cifarelli, V. ; Padera, T.P. ; Rutkowski, J.M. ; Eddens, K.S. ; Egan, C. ; Whitehead, S. ; Herbst, K.L. ; Bunnell, B.A. ; Shawber, C. ; Hucho, T. ; Hinyard, L. ; Al-Ghadban, S. ; Scott, A.O. ; Ostergaard, P. ; Pittman, A. ; Nono Nankam, P.A. ; Scherer, P.E. ; Forner-Cordero, I. ; Damstra, R.J. ; Hendrickx, A. ; Srinivasan, A.
The lipedema common case report form as a research tool: Standardizing lipedema data collection.Blüher, M. ; Bojunga, J. ; Fassnacht, M. ; Führer-Sakel, D.
Neuigkeiten aus Endokrinologie/Diabetologie.Blüher, M.
Treatment potential of oral small-molecule GLP-1 receptor agonists.Strehlau, C. ; Broghammer, H. ; Gebhardt, C. ; Hoffmann, A. ; Hagemann, T. ; Midilli, S. ; Zimmer, R.S. ; Schubert, K. ; Karagiannakou, V. ; Georgiadi, A. ; Ost, M. ; Krüger, M. ; Roth, L. ; Krause, K. ; Klöting-Blüher, N. ; Keller, M. ; Wabitsch, M. ; Nuwayhid, R. ; Stimson, R.H. ; Stumvoll, M. ; Blüher, M. ; Weiner, J. ; Heiker, J.T.
Adipocyte myoglobin is a determinant of energy expenditure and a potential target to limit obesity.Contact
Leipzig University
University of Leipzig Medical Center
Leipzig Center of Metabolism (LeiCeM)
European Association for the Study of Diabetes (EASD)
German Diabetes Association (Deutsche Diabetes Gesellschaft DDG)
Helmholtz Zentrum für Umweltforschung (UFZ)
Ben-Gurion University of the Negev
Karolinska Institutet
German Center for Child and Adolescent Health (DZKJ)
